I suspect Michka was saying the her2 pathology was 3, not that her3 was looked at. Although there is research on her3, I don't think testing for that is readily avaliable.
Michka,
The change in ER status may also be from having treatment, especially her2 targeted therapies that some think may switch status along an
ER and Her2 crosstalk path.
I haven't seen much to support it but..I've always thought individual biopsies from different sites..even at the same time..might give different results.
Given what you have to look at, (if Navelbine doesn't eventually help)
Fulvestrant might be a good choice. Negative progesterone I believe is thought by some to denote less response to antihormonals, but this seems to suggest Faslodex operates differently:
http://clincancerres.aacrjournals.or...3/15/4435.full
And it might actually enhance chemo if you pursue that.
If you have access surgically, you might pursue a sample for
chemosensitivity testing.